Abstract:BACKGROUND AND PURPOSE: Glucagon-like peptide-1 (GLP-1) and glucagon (GCG) receptor dual agonist have promising therapeutic effects in the treatment of obesity and diabetes. Moreover, GLP-1 and cholecystokinin 2 (CCK2 ) dual agonists have been shown to restore pancreas function and improve glycaemic control in preclinical studies. We describe, for the first time, the beneficial effects of GLP-1/glucagon receptor and GLP-1/CCK2 dual agonists, which can be integrated into one peptide, resulting in significant anti-diabetes and anti-obesity effectiveness.EXPERIMENTAL APPROACH: The in vitro potency of this novel peptide Xenopus (x) GLP-1/GCG/CCK2 tri-agonist (xGLP/GCG/gastrin) against GLP-1, GCG, CCK1 and CCK2 receptors was determined on cells expressing the corresponding receptors by cAMP accumulation or ERK1/2 phosphorylation assays. The in vivo anti-diabetes and anti-obesity effects of this tri-agonist xGLP/GCG/gastrin were studied in both db/db and diet induced obesity (DIO) mice.KEY RESULTS: xGLP/GCG/gastrin was a potent and selective GLP-1, GCG and CCK2 tri-agonist. In DIO mice, the metabolic benefits of xGLP-1/GCG/gastrin, such as reduction of body weight and hepatic lipid contents were significantly better than those of the peptide ZP3022 (GLP-1/CCK-2 dual agonist) and liraglutide. In a short-term study in db/db mice, xGLP/GCG/gastrin treatment had considerable effects, increasing islet numbers, islet areas and insulin content. In a long-term treatment study using db/db mice, xGLP-1/GCG/gastrin showed a significantly and sustained improvement in glucose tolerance and glucose control compared with that of liraglutide, ZP3022, cotadutide (GLP-1/GCG dual agonist) and xGLP/GCG-15.CONCLUSIONS AND IMPLICATIONS: These results demonstrate the therapeutic potential of xGLP-1/GCG/gastrin for the treatment of obesity and diabetes.

Glucagon-like peptide-1 analogs: Miracle drugs are blooming?

Gut hormone multi-agonists for the treatment of type 2 diabetes and obesity: advances and challenges

Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management

Small-molecule GLP-1 Secretagogs: Challenges and Recent Advances.

Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease

Glucagon-like peptide-1 receptor: mechanisms and advances in therapy

GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects

Poly-Agonist Pharmacotherapies for Metabolic Diseases: Hopes and New Challenges

GLP-1 and Amylin in the Treatment of Obesity

The clinical experience of GLP-1 receptor agonist drugs

Control of insulin secretion by GLP-1

GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review

An update on peptide-based therapies for type 2 diabetes and obesity

Structural basis for the therapeutic advantage of dual and triple agonists at the human GIP, GLP-1 or GCG receptors

A GLP‐1/glucagon/CCK‐2 receptors tri‐agonist provides new therapy for obesity and diabetes

Pharmacotherapy for Type 2 Diabetes Mellitus: What’s Up and Coming in the Glucagon-Like Peptide-1 (GLP-1) Pipeline?

[A new era for incretins : from GLP-1 receptor agonists to co-agonists and poly-agonists]

Glucagon-like Peptide-1 Receptor Agonists in the Management of Type 2 Diabetes Mellitus and Obesity: The Impact of Pharmacological Properties and Genetic Factors

Pharmacological Advances in Incretin-based Polyagonism – What we know and what we don'tt

GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach

Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists